John Boris
John Boris
believe bit buying created good hints line modest stock top weaker
Anything that hints of a weaker top line doesn't play too well with the Street. We believe there's a tad bit of disconnect, and the modest contraction in the stock has created a good buying opportunity.
avenues beyond cases court decision exhausted february hears largely patent point regain rejection remains supreme
The Supreme Court only hears patent cases approximately 7% of the time. Therefore, the Supreme Court's rejection of the case was largely anticipated and the Appellate court decision remains in place. Merck has exhausted all avenues to regain U.S. exclusivity beyond February 2008, at which point generics are expected.
adds certain depend judge largely ruling stein within
An anticipation ruling would depend largely on how Judge Stein interprets certain wording within the patent. It adds some risk.
anchored attractive believe current downside levels limited offering risk
We believe the downside risk from current levels is limited anchored by Merck offering an attractive 4.4% dividend.
additional expect generic increase price spread
We expect the price spread to increase from 28% to more than 70% with additional generic launches.